ArticleJournal of Cancer2017

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.

Ju Sun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.